For too long, you have had to sacrifice biological performance for automation. Not anymore.
Scale Your Impact.
Introducing IRO®.
The new standard in CGT manufacturing technology.
IRO® delivers superior biological performance alongside the benefits of automation so you can maximize your clinical and commercial impact.
Automate Better Biology with IRO®.
- Compatible with all suspension cell therapies including CAR-T, TIL, TCR-T, NK and CD34+
- Start with ~50M cells (at 50ml) and yield up to 12B cells (at 1L) with high viability
- Achieves higher transduction efficiency and cell yields than the current “gold standard” cell expansion system
- Reduces manufacturing process times by an average of 1-2 days
- Patented OriConnect™ System closes and automates sterile fluid transfer
Accelerate Product Development with IRO®.
IRO® can help you quickly transition from R&D into the clinic, and from the clinic to commercial-scale manufacturing.
- One flexible platform from R&D to GMP for multiple clinical programs
- GMP-ready and 21 CFR Part 11 compliant: shortens tech transfer and optimization times for a faster path to the clinic
- Mitigates risk of process change and comparability between your clinical and commercial stage
- Helps you reach the next value inflection point more quickly
- Increases your ability to secure future funding or partners with a viable plan to reach scale
Scale Your Impact with IRO®.
IRO® combines an efficient and flexible platform with a scalable, digital solution to industrialize precision medicine manufacturing – delivering a return on investment to innovators developing a new generation of therapies.
- Platform built for CGT, not repurposed from biologics
- Reduces labor by 50-70% and manufacturing costs by 30-50%
- Reduces batch failure rates to hit target dose more consistently
- Enables manufacturing in GMP Grade C or D cleanrooms
- Increases throughput per sq ft, ~1000 doses per year in 1000 sq ft
- Facilitates multi-site manufacturing and comparability
"I expected automation, I expected more process insights, but I never expected better biological performance right out of the gate."
Jason Bock, Co-Founder and CEO
CTMC – a joint venture between Resilience + MD Anderson Cancer Center
Get to Know IRO®.
Explore the innovative features that make IRO uniquely IRO.